Publications
Detailed Information
Independent Prognostic Utility of 11 C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, You-Jung | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Lee, Hyun-Jung | - |
dc.contributor.author | Hwang, In-Chang | - |
dc.contributor.author | Park, Jun-Bean | - |
dc.contributor.author | Yoon, Yeonyee | - |
dc.contributor.author | Kim, Hack-Lyoung | - |
dc.contributor.author | Kim, Hyung-Kwan | - |
dc.contributor.author | Kim, Yong-Jin | - |
dc.contributor.author | Cho, Goo-Yeong | - |
dc.contributor.author | Sohn, Dae-Won | - |
dc.contributor.author | Paeng, Jin-Chul | - |
dc.contributor.author | Lee, Seung-Pyo | - |
dc.date.accessioned | 2022-10-12T00:54:39Z | - |
dc.date.available | 2022-10-12T00:54:39Z | - |
dc.date.created | 2022-09-01 | - |
dc.date.created | 2022-09-01 | - |
dc.date.created | 2022-09-01 | - |
dc.date.created | 2022-09-01 | - |
dc.date.created | 2022-09-01 | - |
dc.date.created | 2022-09-01 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.citation | Journal of Nuclear Medicine, Vol.63 No.7, pp.1064-1069 | - |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185919 | - |
dc.description.abstract | © 2022 Society of Nuclear Medicine Inc.. All rights reserved.11C-Pittsburgh compound B positron emission tomography/computed tomography (11C-PiB PET/CT) visualizes the amount of myocardial amyloid deposit and can be used to prognosticate patients with light-chain (AL) cardiac amyloidosis (CA). However, whether 11C-PiB PET/CT has any independent additional prognostic value beyond the commonly used biomarkers remains unknown. Methods: This was a prospective cohort of 58 consecutive patients with ALCA who underwent 11C-PiB PET/CT. Patients were stratified into 2 groups based on a visual assessment on whether there was a myocardial 11C-PiB uptake or not on PET/CT. The primary endpoint was 1-year overall mortality. The independent prognostic utility of 11C-PiB PET/CT was analyzed using net reclassification improvement and integrated discrimination improvement. Results: Among the 58 patients enrolled, 35 patients had a positive myocardial 11C-PiB uptake on PET/CT. Patients with a positive myocardial 11C-PiB PET uptake had a worse 1-year overall survival rate than those with a negative uptake (81.8% vs. 45.5%, P=0.003 by log-rank test). In the multivariate analysis, a positive myocardial 11C-PiB uptake on PET/CT was an independent predictor of 1-year mortality (adjusted hazard ratio 3.382, 95% confidence interval 1.011–11.316, P=0.048). In each subgroup analysis of patients with troponin I ≥0.1 ng/mL, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥1,800 pg/mL, and the difference between free light chains (dFLC) ≥180 mg/mL, the three commonly used biomarkers and its thresholds for staging in AL amyloidosis, Kaplan-Meier curves showed that the patients with a positive myocardial 11C-PiB uptake on PET/CT had a worse prognosis than those with a negative myocardial 11C-PiB uptake, respectively. Additionally, when the result of 11C-PiB PET/CT was added to these three biomarkers, the performance of 1-year mortality prediction significantly improved by net reclassification improvement (11C-PiB PET/CT added to troponin I, 0.861; NT-proBNP, 0.914; dFLC, 0.987) and by integrated discrimination improvement (0.200, 0.156, and 0.108, respectively). Conclusion: 11C-PiB PET/CT is a strong independent predictor of 1-year overall mortality and provides incremental prognostic benefits beyond the three commonly used biomarkers of AL amyloidosis staging. Considering the recent developments of numerous amyloid-targeting molecular imaging agents, further investigations are warranted on whether PET/CT should be included in the risk stratification for patients with ALCA. | - |
dc.language | 영어 | - |
dc.publisher | Kexue Chubaneshe/Science Press | - |
dc.title | Independent Prognostic Utility of 11 C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.2967/jnumed.121.263033 | - |
dc.citation.journaltitle | Journal of Nuclear Medicine | - |
dc.identifier.wosid | 000823739000029 | - |
dc.identifier.scopusid | 2-s2.0-85133848124 | - |
dc.citation.endpage | 1069 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 1064 | - |
dc.citation.volume | 63 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Hack-Lyoung | - |
dc.contributor.affiliatedAuthor | Kim, Hyung-Kwan | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Jin | - |
dc.contributor.affiliatedAuthor | Cho, Goo-Yeong | - |
dc.contributor.affiliatedAuthor | Sohn, Dae-Won | - |
dc.contributor.affiliatedAuthor | Paeng, Jin-Chul | - |
dc.contributor.affiliatedAuthor | Lee, Seung-Pyo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | BRAIN NATRIURETIC PEPTIDE | - |
dc.subject.keywordPlus | ENDOMYOCARDIAL BIOPSY | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.subject.keywordPlus | STAGING SYSTEM | - |
dc.subject.keywordPlus | AL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | NOMENCLATURE | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordAuthor | 11C-Pittsburgh compound B positron emission tomography | - |
dc.subject.keywordAuthor | cardiac amyloidosis | - |
dc.subject.keywordAuthor | mortality | - |
dc.subject.keywordAuthor | risk stratification | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.